Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
about
Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immunogenicity and tolerabilit ...... n children 6-35 months of age.
@ast
Immunogenicity and tolerabilit ...... n children 6-35 months of age.
@en
type
label
Immunogenicity and tolerabilit ...... n children 6-35 months of age.
@ast
Immunogenicity and tolerabilit ...... n children 6-35 months of age.
@en
prefLabel
Immunogenicity and tolerabilit ...... n children 6-35 months of age.
@ast
Immunogenicity and tolerabilit ...... n children 6-35 months of age.
@en
P2093
P1476
Immunogenicity and tolerabilit ...... n children 6-35 months of age.
@en
P2093
Ashwani Arora
Dorothee Kieninger-Baum
Giovanni Della Cioppa
Hans C Rümke
Katia Abarca
Luis Rivera
Maria Lattanzi
Markus Knuf
Paola Pedotti
P304
P356
10.1097/INF.0000000000000462
P577
2014-12-01T00:00:00Z